# Quest Diagnostics (DGX) Stock Analysis: Potential 13.97% Upside Captures Investor Attention

- Link: https://www.directorstalkinterviews.com/quest-diagnostics-dgx-stock-analysis-potential-13-97-upside-captures-investor-attention/4121233365
- Published: 2026-01-05T11:26:34+00:00
- Author: Madison Wilson

Quest Diagnostics Incorporated (NYSE: DGX), a significant player in the healthcare
sector, stands out with a market capitalization of $19.43 billion. This diagnostic
and research titan, headquartered in Secaucus, New Jersey, offers a spectrum of 
diagnostic testing and services domestically and internationally. As the company
continues to innovate and expand, investors have their eyes set on its financial
metrics and market performance to gauge future growth potential.

Currently trading at $173.79, Quest Diagnostics has demonstrated stability within
its 52-week range of $150.33 to $192.35. Despite a modest recent price change of
$0.26, the stock holds a promising potential upside of 13.97%, based on the average
target price of $198.06. This potential makes DGX an attractive consideration for
investors seeking opportunities in the diagnostics and research industry.

Valuation metrics for Quest Diagnostics reveal a forward P/E ratio of 16.75, aligning
it competitively within the healthcare sector. Although other valuation metrics 
like the PEG ratio, Price/Book, Price/Sales, and EV/EBITDA are not available, the
company’s revenue growth of 13.20% and a robust EPS of 8.52 underscore its financial
health and operational efficiency. Particularly notable is the return on equity 
at 14.35%, showcasing the company’s ability to generate profits from its equity 
base.

Quest Diagnostics is also appealing to income-focused investors with its dividend
yield of 1.84% and a sustainable payout ratio of 36.97%. This indicates a balanced
approach to rewarding shareholders while retaining sufficient capital for reinvestment
and growth.

Analyst sentiment towards Quest Diagnostics is predominantly positive, with eight
buy ratings and ten hold ratings. Notably, there are no sell ratings, suggesting
confidence in the company’s market position and future prospects. The target price
range of $166.00 to $215.00 reflects a broad consensus of stability and potential
growth, providing a reassuring backdrop for current and prospective investors.

From a technical perspective, the stock’s 50-day and 200-day moving averages stand
at $181.44 and $177.29, respectively. The Relative Strength Index (RSI) of 59.49
indicates a neutral position, suggesting that the stock is neither overbought nor
oversold at this time. Meanwhile, the MACD and signal line are slightly negative
at -2.53 and -2.13, respectively, which could indicate a period of consolidation
or a potential buying opportunity as market conditions evolve.

Quest Diagnostics, founded in 1967, continues to leverage its extensive network 
of laboratories and service centers to provide vital diagnostic services across 
multiple brands, including AmeriPath, Dermpath Diagnostics, and ExamOne. By catering
to a diverse clientele, from physicians and hospitals to government agencies and
insurers, Quest Diagnostics remains well-positioned to capitalize on the growing
demand for diagnostic information services.

As Quest Diagnostics navigates the evolving healthcare landscape, investors will
be closely monitoring its strategic initiatives and financial performance. With 
a strong market presence and a clear focus on innovation, Quest Diagnostics is poised
to capture further growth, making it a compelling consideration for investors seeking
exposure to the healthcare diagnostics sector.

Share on:
